As a specific inhibitor of the BCR-ABL tyrosine kinase, imatinib becomes the first choice for the treatment of CML due to its high efficacy and low toxicity. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.